Cart
sales@molnova.com
Feladilimab
CAS No. 2252518-85-5
Feladilimab( —— )
Catalog No. M36892 CAS No. 2252518-85-5
Feladilimab (GSK3359609) is an IgG4 monoclonal antibody that is an ICOS agonist.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 375 | Get Quote |
|
| 5MG | 615 | Get Quote |
|
| 10MG | 938 | Get Quote |
|
| 25MG | 1408 | Get Quote |
|
| 50MG | 1822 | Get Quote |
|
| 100MG | 2502 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameFeladilimab
-
NoteResearch use only, not for human use.
-
Brief DescriptionFeladilimab (GSK3359609) is an IgG4 monoclonal antibody that is an ICOS agonist.
-
DescriptionFeladilimab (Anti-ICOS/CD278 Reference Antibody (feladilimab); GSK3359609) is humanized IgG4 anti-ICOS agonist monoclonal antibody. Feladilimab binds to ICOS-expressing T cells. Feladilimab has the potential for the research of cancer.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayChromatin/Epigenetic
-
TargetCOX
-
RecptorCOX | PD-1/PD-L1
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2252518-85-5
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Offidani M, et al. Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety. Drug Des Devel Ther. 2021 Jun 2;15:2401-2415.?
molnova catalog
related products
-
Rofecoxib
A potent, selective and orally active COX-2 inhibitor with IC50 of 26 nM for inhibition of the COX-2-dependent production of PGE2 in human osteosarcoma cells.
-
Bufexamac
Bufexamac is a COX inhibitor for IFN-α release.
-
Triamcinolone
Triamcinolone is a long-acting synthetic corticosteroid.
